PCMA Urges CMS to Protect Pharmacies in Medicare Fair Price Program
Under the Inflation Reduction Act (IRA), for designated drugs that are negotiated by CMS in Medicare Part D, the pharmacy is no longer paid by
PCMA Provides Recommendations for 2026 Medicare Plan Year to Promote Lower Costs and Better Pharmacy Experiences for Patients
By Debjani Mukherjee, Senior Director, Regulatory Affairs, PCMA In November, the Centers for Medicare & Medicaid Services (CMS) released a proposed rule for the Medicare
Drug Formularies: Purposes, Intent, and Challenges
A plan’s formulary (or drug list) is a list of prescription drugs approved for coverage by plan sponsors such as public and private employers, unions,
PCMA Urges CMS to Stabilize the Medicare Part D Plan Marketplace
By Tim Dube, SVP, Policy and Regulatory Insights, Pharmaceutical Care Management Association Last week, PCMA offered recommendations to the Centers for Medicare and Medicaid Services
CMS Should Protect the Financial Health of Pharmacies When Implementing the IRA
By Tim Dube, SVP, Policy and Regulatory Insights, Pharmaceutical Care Management Association If the community pharmacy lobby is right, America’s Medicare beneficiaries may not be
Amid IRA Implementation, PBMs Continue to Deliver Value and Savings for Medicare Beneficiaries
By Tim Dube, SVP, Policy and Regulatory Insights It’s been two years since President Biden signed the Inflation Reduction Act (IRA) into law, whose several
